IL284218B2 - Crystalline and salt forms of 1-methyl-5-(2’-methyl-[1,1’-biphenyl]-yl)-1h-benzo[d][1,2,3]triazole-7-carboxylic acid and pharmaceutical compositions thereof - Google Patents
Crystalline and salt forms of 1-methyl-5-(2’-methyl-[1,1’-biphenyl]-yl)-1h-benzo[d][1,2,3]triazole-7-carboxylic acid and pharmaceutical compositions thereofInfo
- Publication number
- IL284218B2 IL284218B2 IL284218A IL28421821A IL284218B2 IL 284218 B2 IL284218 B2 IL 284218B2 IL 284218 A IL284218 A IL 284218A IL 28421821 A IL28421821 A IL 28421821A IL 284218 B2 IL284218 B2 IL 284218B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pharmaceutical composition
- salt
- tris
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784083P | 2018-12-21 | 2018-12-21 | |
| US201962791571P | 2019-01-11 | 2019-01-11 | |
| US201962882712P | 2019-08-05 | 2019-08-05 | |
| PCT/US2019/067897 WO2020132471A1 (en) | 2018-12-21 | 2019-12-20 | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL284218A IL284218A (en) | 2021-08-31 |
| IL284218B1 IL284218B1 (en) | 2026-01-01 |
| IL284218B2 true IL284218B2 (en) | 2026-05-01 |
Family
ID=69185721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284218A IL284218B2 (en) | 2018-12-21 | 2019-12-20 | Crystalline and salt forms of 1-methyl-5-(2’-methyl-[1,1’-biphenyl]-yl)-1h-benzo[d][1,2,3]triazole-7-carboxylic acid and pharmaceutical compositions thereof |
Country Status (22)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060390A1 (en) | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| CA3091792A1 (en) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| KR20230078997A (ko) | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
| WO2025227007A1 (en) * | 2024-04-26 | 2025-10-30 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014128669A2 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| WO2018197997A1 (en) * | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7622000A (en) * | 1999-10-01 | 2001-05-10 | Institute Of Molecular And Cell Biology | Compounds for the treatment of viral-mediated diseases |
| JP2007015952A (ja) * | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| MX2010010300A (es) | 2008-03-19 | 2010-10-26 | Osi Pharm Inc | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9360932B1 (en) | 2012-08-29 | 2016-06-07 | Intellect Motion Llc. | Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture |
| CN103965133B (zh) * | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| MX2018008169A (es) | 2015-12-30 | 2019-02-20 | Agios Pharmaceuticals Inc | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| CA3091792A1 (en) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| US20230285364A1 (en) * | 2020-06-24 | 2023-09-14 | Servier Pharmaceuticals Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| KR20230078997A (ko) * | 2020-08-27 | 2023-06-05 | 르 라보레또레 쎄르비에르 | 병용 암 요법에서의 dhodh 저해제 화합물의 용도 |
-
2019
- 2019-12-20 BR BR112021012305-9A patent/BR112021012305A2/pt unknown
- 2019-12-20 PE PE2025003120A patent/PE20260309A1/es unknown
- 2019-12-20 KR KR1020217022945A patent/KR20220035022A/ko active Pending
- 2019-12-20 CR CR20210394A patent/CR20210394A/es unknown
- 2019-12-20 TW TW108147117A patent/TWI875727B/zh active
- 2019-12-20 WO PCT/US2019/067897 patent/WO2020132471A1/en not_active Ceased
- 2019-12-20 MA MA054541A patent/MA54541A/fr unknown
- 2019-12-20 IL IL284218A patent/IL284218B2/en unknown
- 2019-12-20 CN CN201980091991.XA patent/CN113508108B/zh active Active
- 2019-12-20 PE PE2021001052A patent/PE20212197A1/es unknown
- 2019-12-20 EP EP19839747.3A patent/EP3898597A1/en active Pending
- 2019-12-20 JO JOP/2021/0147A patent/JOP20210147A1/ar unknown
- 2019-12-20 JP JP2021536323A patent/JP2022515239A/ja active Pending
- 2019-12-20 MX MX2021007536A patent/MX2021007536A/es unknown
- 2019-12-20 UA UAA202104251A patent/UA130491C2/uk unknown
- 2019-12-20 AU AU2019403396A patent/AU2019403396B2/en active Active
- 2019-12-20 GE GEAP201915700A patent/GEP20247683B/en unknown
- 2019-12-20 GE GEAP202415700A patent/GEAP202415700A/en unknown
- 2019-12-20 US US17/416,910 patent/US12297179B2/en active Active
- 2019-12-20 SG SG11202106526UA patent/SG11202106526UA/en unknown
-
2020
- 2020-01-09 PH PH1/2021/551495A patent/PH12021551495A1/en unknown
-
2021
- 2021-06-18 CL CL2021001640A patent/CL2021001640A1/es unknown
- 2021-06-21 NI NI202100055A patent/NI202100055A/es unknown
- 2021-07-15 CO CONC2021/0009309A patent/CO2021009309A2/es unknown
-
2024
- 2024-08-07 JP JP2024131002A patent/JP7749080B2/ja active Active
-
2025
- 2025-05-07 US US19/201,581 patent/US20250270175A1/en active Pending
- 2025-09-22 JP JP2025156833A patent/JP2026001058A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014128669A2 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| WO2018197997A1 (en) * | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| BRITTAIN, HARRY G, POLYMORPHISM IN PHARMACEUTICAL SOLIDS., 31 December 2009 (2009-12-31) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288909A (en) | Methods of making bempedoic acid and compositions of the same | |
| AU2022221446A1 (en) | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | |
| IL283539A (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| IL283409B1 (en) | History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them | |
| IL250740B (en) | Piperazine-2,5-dione derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
| HUE052332T2 (hu) | Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére | |
| EP3412292B8 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
| IL279702A (en) | Pyridine and pyridazine derivatives are converted in positions 3 and 5 and their pharmaceutical uses | |
| HUE064995T2 (hu) | Piridinil-szulfonamid-származékok, gyógyszerkészítmények és azok felhasználása | |
| EP3590498A4 (en) | PREPARATION, INCLUDING AN INCLUSION COMPLEX OF VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREFOR, FOR ORAL ADMINISTRATION | |
| ZA202104064B (en) | R-type pyridyloxycarboxylic acid, salt and ester derivative thereof, and preparation method therefor, and herbicidal composition and application thereof | |
| EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
| MX394624B (es) | Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos. | |
| MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
| IL285421A (en) | Indazolyl-isoxazole derivatives, their preparation and pharmaceutical compositions containing them | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| BR112017021669A2 (pt) | formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações | |
| HUE055904T2 (hu) | 2-([1,2,3]triazol-2-il)-benzoesav-származékok elõállítása | |
| IL284218A (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof | |
| WO2013169746A3 (en) | N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide | |
| IL272284A (en) | Thiazolopyridine derivatives, their preparation and pharmaceutical compositions containing them | |
| EP3898582A4 (en) | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF | |
| EP3404020A4 (en) | PYRIDINOL DERIVATIVE OR PHARMACEUTICALLY SAFE SALT THEREOF AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE | |
| PL3778609T3 (pl) | Pochodne penamu lub ich sole, kompozycje farmaceutyczne i ich zastosowanie | |
| EP3752142A4 (en) | ANTIBACTERIAL AGENTS: SOLUBLE SALT AND AQUATIC FORMULATIONS OF PYRONINES |